ATOS Atossa Therapeutics Inc: רווח נקי למניה ב-12 החודשים האחרונים

Atossa Therapeutics (ATOS) is striving for pricing power through Endoxifen, which is transforming hormonal care for breast cancer. This chart of the share price reflects an EPS of -10.60 as the company penetrates the women's oncology market through innovation. Business prospects rely on the success of clinical trials and sufficient liquidity to cover testing costs.

Atossa Therapeutics (ATOS) invests in biochemical research to combat breast cancer. The rolling year earnings per share trend reflects the efficiency of these expenditures, comparing current financial results with the same period last year. By analyzing the EPS YoY volatility over the last 12 months, an investor can discern the real rate of capital growth. High volatility in this metric directly impacts the issuer's market capitalization.